还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

* _$ k: [4 `/ u" C请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
; L" E3 q) r" Y+ [
3 _) B9 ]& S# A$ r8 T( z: J
Sub-category:
6 W1 G+ o' y; A5 p4 B$ KMolecular Targets


Category:
# ]1 }; u% j) G+ q: ATumor Biology
% p' q3 H% d: H# a) m5 U

Meeting:
2011 ASCO Annual Meeting


) R  o) U( U1 }; E5 r) j% X1 @Session Type and Session Title:
) {7 X" _- c( _* `; T9 E7 I# i4 tPoster Discussion Session, Tumor Biology

" w5 U- @! O4 T. X. Q8 ^
# @9 q/ J  Y* v3 h8 qAbstract No:
10517

) {5 \2 ?( }) G" p3 y
Citation:
& I/ X3 H3 \7 |  V* M- lJ Clin Oncol 29: 2011 (suppl; abstr 10517)


Author(s):
2 }( O, e6 h2 FJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China


* C5 q7 s2 r  e( p: g
; D8 Q% V/ t9 t$ BAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures
, Q" L! O& o6 A* ^6 B7 w( _
Abstract:
- T1 C+ `* U% w5 s/ s  y6 W: l5 W
* G; r. u5 ], J  R% l: d2 y6 q
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

3 B9 W7 v+ a( B4 B                               
登录/注册后可看大图

) U3 ]5 v3 c7 \8 h# ?2 |* \1 E没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

3 W7 X. f- w9 W* k5 x& W) u化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

, ^7 {( g7 w, V6 |. U易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

7 p0 e7 q" X* o3 Y. d平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊